Entries by Therese Nesse

Cytovation to Advance Development of CY-101 for Cancers Driven by Dysfunction of Wnt/β-catenin Signalling Under International Nonproprietary Name of Getacatetide

Plans to initiate Phase 2 clinical trial in Adrenocortical Carcinoma in early 2026 through unique partnership between Cytovation, Cancer Research UK and the Norwegian Cancer Society Bergen, Norway, July 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that the International Nonproprietary Names […]

Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts

• New funds provided largely by existing investors, led by Sandwater  • Phase 2 trial to be delivered through novel agreement between Cytovation, Cancer Research UK and the Norwegian Cancer Society  • New preclinical data highlighting potential of CY-101 in ACC and other cancer types driven by a dysfunctional Wnt/β-catenin pathway, including colorectal cancer, to […]

Cytovation appoints Martin Dewhurst to its Board of Directors

February 13, 2025 03:00 ET | Source: Cytovation Brings over 30 years of life sciences industry experience Co-led the McKinsey Global Life Sciences practice Bergen, Norway, February 12, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces the appointment of Mr. Martin Dewhurst to its […]

Cytovation to present full safety and efficacy data from the CICILIA Phase I/IIa trial evaluating CY-101 in solid tumors at ESMO 2024

CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/β-catenin signalling CY-101 granted Orphan Drug Designation in US for the treatment of Adrenocortical Carcinoma, a Wnt/β-catenin driven tumor type Bergen, Norway, September 13, 2024 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional […]

Cytovation announces appointment of Ellen Lubman, MBA to its Board of Directors

Bergen, Norway, December 20, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumour membrane immunotherapy CyPep-1, today announced the election of Ellen Lubman, MBA, to its Board of Directors. “We are excited to welcome Ellen, who brings extensive experience and a well-proven track record across business […]

Cytovation Reports Promising Interim Results from Phase 1/2a CICILIA Study with CyPep-1 in Solid Tumors

Findings confirm unique dual mechanism of action and fast-to-market target indication for potentially registrational trial All CICILIA trial endpoints met, with CyPep-1 demonstrating consistent safety profile across tumor types and strong early signals of efficacy. Further evidence for novel dual mechanism of action combining inhibition of Wnt/βcatenin oncogenic pathway with tumor-specific cell destruction and immune […]

Cytovation appoints Olav Hellebø to its Board of Directors

Bergen, Norway, July 5th, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces the appointment of Olav Hellebø to its Board of Directors.  Mr. Hellebø brings extensive international leadership experience, both in the US and Europe, across major pharmaceutical and biotechnology companies. […]

Cytovation raises $8 million in Series A extension financing round for clinical advancement of CyPep-1, a first-in-class targeted tumor membrane immunotherapy

Brings total Series A funding to over $28 million allowing CyPep-1 to advance into Phase 2  Bergen, Norway, June 2, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces the successful closing of its $8 million (NOK 85 million) Series A extension […]